Pharmasmile

Pink October 2025: Raising awareness, screening and taking action against breast cancer.

Pink ribbon in the palm of a hand with a title in the foreground introducing the article on pink October.

Pink October 2025: Raising awareness, screening and taking action against breast cancer.

📌 What is Pink October? A worldwide mobilization

Every year, the month of October is decked out in pink to remind us of a major public health issue: the fight against breast cancer. The pink ribbonhas become a universal symbol, embodying solidarity, prevention and hope.

The story of Pink October began in 1992 in the United Statesunder the impetus of Alexandra Penney (Self Magazine) and Evelyn H. Lauder (Estée Lauder). The initiative soon spread internationally, and in 1994, France adopted Pink October with the "Le Cancer du Sein, Parlons-en" campaign.

Today, October Rose is more than just a symbolic campaign: it's a time for collective time for collective mobilization where associations, institutions and healthcare professionals work together to promote early detection and support research.

📊 Breast cancer in figures: a public health priority

Breast cancer remains the most common cancer in women, and is a major public health issue:

  • 61,000 new cases each year in France (Santé Publique France)
  • 12,000 deaths a year
  • 33 % of female cancers worldwide
  • 60% detected at an early stage
  • 87% 5-year survival rate thanks to medical advances

👉 These figures are a reminder of the crucial importance of prevention and organized screeningparticularly between the ages of 50 and 74, with mammography every two years.

🔍 The main risk factors for breast cancer

Several factors influence the risk of developing breast cancer:

  • Family history (mutations BRCA1/BRCA2)
  • Age (increased risk after age 50)
  • Prolonged hormonal exposure
  • Obesity, sedentary lifestyle, alcohol consumption
  • Environmental factors and endocrine disruptors

📌 According to experts, nearly 20,000 cases could be prevented every year by acting on modifiable risk factors (lifestyle, prevention, physical activity).

⚕️ Therapeutic advances and medical research

💉 Innovative, personalized treatments

In recent years, research has led to major advances:

  • Trodelvy + Keytruda an effective combination for triple-negative cancers expressing PD-L1.
  • Itovebi (inavolisib) A new targeted therapy for metastatic HR+/HER2- cancers with PIK3CA mutation.

These approaches individualize treatmentreduce side effects and improve quality of life.

🌐 Artificial intelligence for diagnosis

AI now plays a central role in :

  • L'medical imaging (mammography, ultrasound, MRI)
  • L'predictive analysis risk analysis
  • The clinical research with big data analysis

AI-assistedAI-assisted portable ultrasound are also being tested to improve access to screening in under-medicalized areas.

🧑‍⚕️ The essential role of pharmacists during Pink October

The pharmacistsas local healthcare professionals, are key players in the key players in this fight. They have three main roles to play:

🎯 Raising awareness and providing information

  • Distribution of prevention materials
  • Warning signs (nodule, discharge, skin changes)
  • Self-monitoring education

🤝 Promoting screening

  • Referral to radiology centers
  • Collaboration with CPTS, associations and local structures

💬 Supporting patients

  • Advice on treatment side effects
  • Help with medication compliance
  • A place to listen and reassure

The pharmacies are also taking part in local mobilizationby putting up ribbons and posters, or organizing awareness-raising events.

🌍 Pink October: a collective movement for the future

October Rose is much more than a simple annual campaign: it is a mobilization of medical and community mobilization that reminds everyone of the importance of prevention and solidarity.

Each player has a role to play:

  • The patients and their familiesBy being attentive to warning signs and participating in screening.
  • The healthcare professionalsby providing support and guidance.
  • The researchersby pursuing therapeutic innovation.
  • Visit institutions and associationsby coordinating awareness-raising initiatives.

This month of October is a reminder that the fight against breast cancer doesn't stop on October 31. It continues all year roundthrough :

  • support for research,
  • easier access to screening,
  • improving care pathways,
  • and solidarity with the women affected.

✨ Together, patients, caregivers, associations and citizens, we're making Pink October a real lever of hope and progress for tomorrow.

❓ FAQ - Pink October and breast cancer

  1. Why is the month of October associated with the fight against breast cancer?
     Because since 1992, the pink ribbon has become a worldwide symbol, worn every October to remind people of the importance of prevention and screening.
  2. At what age should I have a mammogram?
     Between the ages of 50 and 74, every two years, as part of the organized screening program.
  3. Can breast cancer be prevented?
     It can't be totally prevented, but a healthy lifestyle greatly reduces the risk.
  4. What are the first warning signs to look out for?
     A nodule, a change in the skin or nipple, or an abnormal discharge should raise the alarm.
  5. What role does artificial intelligence play in the fight against breast cancer?
     It improves early detection, helps personalize treatments and accelerates clinical research.
  6. Why are pharmacists essential during Pink October?
     Because they are accessible, educational and a crucial link in informing, guiding and supporting patients.

📚 Useful resources

  • Association Ruban Rose : https://www.cancerdusein.org/
  • Ligue contre le Cancer : https://www.ligue-cancer.net/octobre-rose
  • Breast Cancer Research Foundation: https://www.bcrf.org/
  • Xiong X,et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19;10(1):49.
  • Giaquinto AN, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495.
    Tolaney SM, et al. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20(31):2343-2355.
  • Turner NC, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024 Oct 31;391(17):1584-1596.
  • McCrorie AD, et al.. Mapping the current landscape of locoregional therapy de-escalation trials in early breast cancer: a systematic review. NPJ Breast Cancer. 2025 Mar 30;11(1):32.
  • https://www.cpts-sud77.fr/prevention/octobre-rose-fete-ses-30-ans-en-france/ (visited on 09/25/2025)
  • https://arxiv.org/abs/2411.07322?
  • Amirehsan Ghasemi, et al. Explainable artificial intelligence in breast cancer detection and risk prediction: A systematic scoping review. Cancer Innovation 2024;3:e136

Discover our other articles

Back to top